US panel rejects breast cancer indication for J&J's Doxil
This article was originally published in Scrip
Executive Summary
The US FDA's oncologic drugs advisory committee has unanimously recommended against adding a breast cancer indication to Centocor Ortho Biotech's (Johnson & Johnson) anthracycline chemotherapeutic Doxil (pegylated liposomal doxorubicin). The committee said that the addition of Doxil to Sanofi-Aventis's Taxotere (docetaxel) in first-line metastatic patients did not represent a favourable risk/benefit analysis.
You may also be interested in...
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.